Artiva Biotherapeutics, Inc.(ARTV) - 2024 Q3 - Quarterly Results

Financial Performance - Collaboration revenue was $0 for Q3 2024, a decrease from$26.7 million in Q3 2023, due to the termination of the Merck collaboration[5] - Research and development expenses for Q3 2024 were $13.5 million, slightly up from$13.1 million in Q3 2023[6] - General and administrative expenses increased to $4.8 million in Q3 2024 from$2.8 million in Q3 2023[6] - Net loss for Q3 2024 was $17.5 million, compared to a net income of$11.3 million in Q3 2023[6] Cash and Assets - Artiva Biotherapeutics reported cash, cash equivalents, and investments of $199.6 million as of September 30, 2024, expected to fund operations at least through the end of 2026[5] - Total assets increased to$225.6 million as of September 30, 2024, from $105.1 million at the end of 2023[10] Corporate Developments - Artiva appointed Dr. Alison Moore to its Board of Directors in October 2024, bringing over 25 years of experience in biotechnology and cell therapy manufacturing[3] - Artiva completed a$179.0 million initial public offering in July 2024, selling 14,920,000 shares at $12.00 per share[3] Clinical Trials and Research - Initial data for AlloNK® in autoimmune indications is expected in the first half of 2025[1] - AlloNK® is currently in clinical trials for systemic lupus erythematosus and other autoimmune diseases[7]